<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82352">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01949948</url>
  </required_header>
  <id_info>
    <org_study_id>REK 2011/2435</org_study_id>
    <nct_id>NCT01949948</nct_id>
  </id_info>
  <brief_title>Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke</brief_title>
  <acronym>NOR-TEST</acronym>
  <official_title>Randomised Trial of Tenecteplase vs. Alteplase for Recanalisation in Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lars Thomassen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Research Council of Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <authority>Norway: Norwegian Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND: Alteplase dissolves blood vessel clots in acute ischemic stroke and is the only
      approved acute drug treatment &lt;4½ hours of stroke onset. The overall benefit from alteplase
      is substantial, but up to 2/3 of patients with large artery clots may not achieve reopening
      of the vessel and up to 40% of the patients may remain severely disabled or die, leaving
      substantial room for improvement. Tenecteplase, widely used in coronary heart disease, may
      be more effective and may have less bleeding complications than alteplase, and may be the
      drug of choice also in stroke.

      HYPOTHESIS: Tenecteplase may be given safely to patients with acute ischemic stroke at a
      dose that is associated with improved clinical outcome compared with existing treatment
      options.

      AIMS: To compare efficacy and safety of tenecteplase vs. alteplase given &lt;4½ hours after
      symptom onset.

      STUDY ENDPOINTS: The primary study endpoint is excellent clinical outcome at 3 months
      (effect). Secondary study endpoints are major early clinical improvement (effect) and
      bleeding complications (safety).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HYPOTHESIS: 1) Tenecteplase 0.4 mg/kg  may be given safely to patients with acute ischaemic
      stroke &lt;4½ hours after stroke onset. 2) Tenecteplase 0,4 mg/kg (single bolus)has superior
      efficacy and safety compared with alteplase 0.9 mg/kg (10% bolus + 90% infusion/60 minutes)
      when given within 4 ½ hours after stroke onset.

      DESIGN: NOR-TEST is a multi-centre PROBE (prospective randomised, open-label, blinded
      endpoint) trial with randomisation tenecteplase:alteplase 1:1.

      POWER CALCULATION: NOR-TEST aims at detecting a 9 % higher percentage excellent outcome with
      tenecteplase vs. alteplase (r1=0.40; r2=0.49; OR 1.44; power 0.8), and will include 954
      patients during 3 years.

      PATIENT RECRUITMENT: All patients found eligible for thrombolytic therapy are eligible for
      NOR-TEST, i.e. NOR-TEST changes neither inclusion nor exclusion criteria. The number of
      patients treated at a participating centre will therefore essentially remain unchanged.
      Estimated 400 patients are thrombolysed per year in participating centres. Allowing for 20%
      of patients not being included in NOR-TEST, the total number of patients (n=954) will still
      be met.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Functional handicap</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>modified Rankin Scale score (mRS) 0-1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptomatic cerebral hemorrhage</measure>
    <time_frame>24-36 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Haemorrhagic transformation (haemorrhagic infarct / haematoma) as defined by CT (or MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic transformation</measure>
    <time_frame>24-36 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Any hemorrhagic infarct or parenchymal hematoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major neurological improvement</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reduction of ≥4 points on the National Institutes of Health Stroke Scale (NIHSS) compared with baseline (for patients with NIHSS ≥4 on admission)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Major neurological improvement</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sliding dichotomy/responder analysis: Excellent outcome is defined as mRS 0 with baseline NIHSS ≤7, as mRS 0-1 with baseline NIHSS 8-14, as mRS 0-2 with baseline NIHSS ≥15</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">954</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Tenecteplase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.4 mg/kg single bolus intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alteplase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenecteplase</intervention_name>
    <description>0.4 mg/kg single bolus intravenously</description>
    <arm_group_label>Tenecteplase</arm_group_label>
    <other_name>Metalyse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase</intervention_name>
    <description>0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously</description>
    <arm_group_label>Alteplase</arm_group_label>
    <other_name>Actilyse</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Ischaemic stroke with measurable deficit on NIH Stroke Scale

          -  All stroke sub-types, severities and vascular distributions,a visible arterial
             occlusion is not required for inclusion

          -  Treatment within 4 ½ hours of stroke onset

          -  Patients awakening with symptoms are defined by the time last observed normal and
             awake

          -  Informed written consent signed by the patient, verbal consent from the patients as
             witnessed by a non-participating health care person, or consent by the signature of
             the patient's family must be provided before treatment

        Exclusion Criteria:

          -  Patients with premorbid modified Rankin Scale (mRS) score ≥3

          -  Patients for whom a complete NIH Stroke Score cannot be obtained

          -  Hemiplegic migraine with no arterial occlusion on baseline CT

          -  Seizure at stroke onset and no visible occlusion on baseline CT

          -  Intracranial haemorrhage on baseline CT

          -  Clinical presentation suggesting subarachnoid haemorrhage even if baseline CT is
             normal

          -  Large areas of hypodense ischaemic changes on baseline CT

          -  Patients with primary endovascular treatment

          -  Patients with systolic blood pressure &gt;185 mm Hg or diastolic blood pressure &gt;110 mm
             Hg

          -  Female, pregnant or breast feeding

          -  Known bleeding diathesis

          -  Use of oral anticoagulants and International Normalized Ratio (INR) ≥1,4

          -  Heparin &lt;48 hours and increased Activated partial thromboplastin tike (APTT)

          -  Low molecular weight heparin(oid) &lt;24 hours

          -  Any other investigational drug &lt;14 days

          -  Sepsis

          -  Patients with arterial puncture at a noncompressible site or lumbar puncture &lt;7 days

          -  Major surgery or serious trauma &lt;14 days

          -  Gastrointestinal or urinary tract hemorrhage &lt;14 days

          -  Clinical stroke &lt;2 months

          -  History of intracranial haemorrhage

          -  Brain neurosurgery &lt;2 months

          -  Serious head trauma &lt;2 months

          -  Pericarditis

          -  Any serious medical illness likely to interact with treatment

          -  Confounding pre-existent neurological or psychiatric disease

          -  Unlikely to complete follow-up

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Thomassen, MD PhD Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. Neurology, Haukeland University HospitalBergen, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrike Waje-Andreassen, MD PhD Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Dept. Neurology, Haukeland University Hospital, Bergen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicola Logallo, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. Neurology, Haukeland University Hospital, Bergen, Norway</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lars Thomassen, MD PhD Prof</last_name>
    <phone>+47 55 97 50 00</phone>
    <email>ltho@haukeland.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicola Logallo, MD PhD</last_name>
    <phone>+47 55 97 50 00</phone>
    <email>nalo@helse-bergen.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Waje-Andreassen, MD PhD Prof</last_name>
      <phone>+47 55 97 50 00</phone>
      <email>uwan@haukeland.no</email>
    </contact>
    <contact_backup>
      <last_name>Lars Thomassen, MD PhD Prof</last_name>
      <phone>+47 55 97 50 00</phone>
      <email>ltho@haukeland.no</email>
    </contact_backup>
    <investigator>
      <last_name>Nicola Logallo, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nordland Hospital</name>
      <address>
        <city>Bodø</city>
        <zip>8092</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Drammen Hospital</name>
      <address>
        <city>Drammen</city>
        <zip>3004</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl F Amthor, MD</last_name>
      <phone>+47 32803693</phone>
      <email>Karl-Friedrich.Amthor@vestreviken.no</email>
    </contact>
    <investigator>
      <last_name>Karl F Amthor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Østfold Hospital Fredrikstad</name>
      <address>
        <city>Fredrikstad</city>
        <zip>1639</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Førde Central Hospital</name>
      <address>
        <city>Førde</city>
        <zip>6800</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdalena Stankiewicz-Pietrzak, MD</last_name>
      <phone>57839000</phone>
      <email>magdalena.stankiewicz@helse-forde.no</email>
    </contact>
    <investigator>
      <last_name>Magdalena Stankiewicz-Pietrzak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haugesund Hospital</name>
      <address>
        <city>Haugesund</city>
        <zip>5516</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Molde Hospital</name>
      <address>
        <city>Molde</city>
        <zip>6400</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Åse Hagen Morsund, MD</last_name>
      <phone>+47 71120000</phone>
      <email>Ase.hagen.morsund@helse-mr.no</email>
    </contact>
    <investigator>
      <last_name>Åse H Morsund, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Nordbyhagen</city>
        <zip>1474</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ullevål University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Telemark Hospital</name>
      <address>
        <city>Skien</city>
        <zip>3710</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hosital</name>
      <address>
        <city>Stavanger</city>
        <zip>4017</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Olav Hospital NTNU</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tønsberg Hospital</name>
      <address>
        <city>Tønsberg</city>
        <zip>3100</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reidar Kloster, MD</last_name>
      <phone>+47 33 32 44 46</phone>
      <email>reidar.kloster@siv.no</email>
    </contact>
    <investigator>
      <last_name>Reidar Kloster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 24, 2013</lastchanged_date>
  <firstreceived_date>September 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Haukeland University Hospital</investigator_affiliation>
    <investigator_full_name>Lars Thomassen</investigator_full_name>
    <investigator_title>Senior Consultant neurologist; Professor</investigator_title>
  </responsible_party>
  <keyword>treatment, intervention, thrombolysis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Tenecteplase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
